A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure.
about
Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure.K201 improves aspects of the contractile performance of human failing myocardium via reduction in Ca2+ leak from the sarcoplasmic reticulumK201 (JTV519) suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2 irrespective of FKBP12.6 associationAnalysis of calstabin2 (FKBP12.6)-ryanodine receptor interactions: rescue of heart failure by calstabin2 in miceEffect of Calstabin1 depletion on calcium transients and energy utilization in muscle fibers and treatment opportunities with RyR1 stabilizersThree-dimensional visualization of FKBP12.6 binding to an open conformation of cardiac ryanodine receptorCGP-37157 inhibits the sarcoplasmic reticulum Ca²+ ATPase and activates ryanodine receptor channels in striated muscle.The ryanodine receptor in cardiac physiology and disease.2APB- and JTV519(K201)-sensitive micro Ca2+ waves in arrhythmogenic Purkinje cells that survive in infarcted canine heart.Designing calcium release channel inhibitors with enhanced electron donor properties: stabilizing the closed state of ryanodine receptor type 1.Ryanodine receptor-targeted anti-arrhythmic therapy.JTV519 (K201) reduces sarcoplasmic reticulum Ca²⁺ leak and improves diastolic function in vitro in murine and human non-failing myocardiumCalcium cycling proteins and heart failure: mechanisms and therapeuticsCPU86017: a novel Class III antiarrhythmic agent with multiple actions at ion channels.Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy.Mechanisms and potential therapeutic targets for ventricular arrhythmias associated with impaired cardiac calcium cycling.Ryanodine receptor-mediated arrhythmias and sudden cardiac death.Ion channels, transporters, and pumps as targets for heart failure therapyPharmacological characteristics and clinical applications of K201.Targeting ryanodine receptors for anti-arrhythmic therapy.Ryanodine receptor patents.Bcl-2 and FKBP12 bind to IP3 and ryanodine receptors at overlapping sites: the complexity of protein-protein interactions for channel regulation.Calcium Signaling and Cardiac Arrhythmias.Function of Ca(2+) release channels in Purkinje cells that survive in the infarcted canine heart: a mechanism for triggered Purkinje ectopy.Effects of K-201 on the calcium pump and calcium release channel of rat skeletal muscle.Reconstitution of local Ca2+ signaling between cardiac L-type Ca2+ channels and ryanodine receptors: insights into regulation by FKBP12.6.Chiral separation of racemate CPU86017, an anti-arrhythmic agent, produces stereoisomers possessing favourable ion channel blockade and less alpha-adrenoceptor antagonism.Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs.New Insights in Cardiac Calcium Handling and Excitation-Contraction Coupling.Abrupt changes in FKBP12.6 and SERCA2a expression contribute to sudden occurrence of ventricular fibrillation on reperfusion and are prevented by CPU86017.
P2860
Q24530067-DDBAE084-4DF3-4961-951C-E172E6BAF3B8Q24645531-E1D4C8F4-E64D-4037-9D28-B817EF12F440Q24684879-422B1F52-3087-44FA-8911-251B286EB277Q28504805-28724BB3-6F21-44BF-A276-D523F2B84968Q28535427-13E7D62A-AF84-4FB6-96B4-9FDFA0FD706FQ34352742-645AB752-1703-4CE6-B3C9-E4787F006442Q34458492-06DA20E2-C444-44C9-8CEC-0A325533E815Q34505314-A1E897A0-F985-43AA-AF05-A61698E5B558Q34893439-EBBB4B96-CD86-4D0C-998F-757ED88FF0E1Q35647401-9321B31E-5472-45BB-B868-468BCA339521Q36225207-3F066B9D-77B9-4C3C-9F1F-CE95E661468AQ36253971-AF7EAF0F-7577-4F8A-B8C7-BF9A0EF1BDF8Q36497155-6F60FEC0-BD01-4628-A07F-FAEF6E406046Q36589376-F4CDF94A-49D3-41BA-983E-00628AD978D9Q36837270-7FB76949-E8F1-46BF-8D7B-F9BA1BCA7AF3Q37025197-61EDBAE5-DE6D-4A9A-96A1-4FD1D9405A6AQ37248371-ACFC84FB-0B16-4A13-A21A-E7FC23D68D13Q37443760-F7606B2A-D553-499E-94FE-AB52B5F60316Q37481632-1CCD26C2-C702-4176-94B1-E693344A6379Q37885158-AD763D09-8213-4C2F-A6DA-643AA5772CCEQ38054907-05FB19AD-3592-43A0-911A-5B238ACBC2D1Q38502062-35DE5009-FFE7-4B53-9FCB-5DF5323463EDQ39360546-8CCFBA87-04A9-44FF-AD02-B77E9C966B67Q42058529-3F318301-6B1C-44A0-8C54-C8D8D065B2FCQ46610397-E25CBB3D-06EA-4F48-BBCC-F9E259ABD648Q46622472-B9E1F3DB-3025-49D1-8B59-34D4946F5CDBQ46821556-8FAE8B54-B7D8-4268-9BDE-F3FB1D16721BQ47366125-1601EC39-44A1-4204-A3AC-3FE427FD63AEQ49689341-31B8C97D-6D74-49DB-BDD0-FFD0A1208DF1Q53552559-47D4E504-14BF-4540-A56A-EF9F27FEDC9D
P2860
A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
A new cardioprotective agent, ...... ine receptor in heart failure.
@en
A new cardioprotective agent, ...... ine receptor in heart failure.
@nl
type
label
A new cardioprotective agent, ...... ine receptor in heart failure.
@en
A new cardioprotective agent, ...... ine receptor in heart failure.
@nl
prefLabel
A new cardioprotective agent, ...... ine receptor in heart failure.
@en
A new cardioprotective agent, ...... ine receptor in heart failure.
@nl
P2093
P2860
P1476
A new cardioprotective agent, ...... ine receptor in heart failure.
@en
P2093
Masafumi Yano
Masahiro Doi
Masateru Kohno
Masunori Matsuzaki
Michihiro Kohno
Shigeki Kobayashi
Shinichi Okuda
Takahiro Tokuhisa
Tetsuro Oda
Tomoko Ohkusa
P2860
P304
P356
10.1152/AJPHEART.00722.2002
P577
2002-11-14T00:00:00Z